Regulatory BMS bags first approval for myeloma CELMoD Zenbexus PharmaphorumBristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.HematologyRead full story pharminent August 14, 2026 (Last updated: August 21, 2026) Pharmaphorum Bristol Myers Squibb’s CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma. Hematology Read full story Post navigation Previous: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene TherapyNext: BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026